Telomir Pharmaceuticals, Inc.’s (NASDAQ:TELO) Lock-Up Period To End Tomorrow

Telomir Pharmaceuticals’ (NASDAQ:TELO) lock-up period is set to end on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its IPO on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Telomir Pharmaceuticals Stock Performance

TELO stock opened at $3.42 on Tuesday. The stock’s 50-day moving average is $4.69. Telomir Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $20.72.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Monday, May 13th. The company reported ($0.23) earnings per share for the quarter.

Hedge Funds Weigh In On Telomir Pharmaceuticals

An institutional investor recently bought a new position in Telomir Pharmaceuticals stock. Bank of New York Mellon Corp bought a new position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,165 shares of the company’s stock, valued at approximately $241,000. Bank of New York Mellon Corp owned approximately 0.17% of Telomir Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.